Author Correction: High- or low-dose preoperative ipilimumab plus nivolumab in stage III urothelial cancer: the phase 1B NABUCCO trial

Jeroen van Dorp; Christodoulos Pipinikas; Britt B M Suelmann; Niven Mehra; Nick van Dijk; Giovanni Marsico; Maurits L van Montfoort; Sophie Hackinger; Linde M Braaf; Tauanne Amarante; Charlaine van Steenis; Kirsten McLay; Antonios Daletzakis; Daan van den Broek; Maaike W van de Kamp; Kees Hendricksen; Jeantine M de Feijter; Thierry N Boellaard; Richard P Meijer; Antoine G van der Heijden; Nitzan Rosenfeld; Bas W G van Rhijn; Greg Jones; Michiel S van der Heijden

doi:10.1038/s41591-023-02500-7

Author Correction: High- or low-dose preoperative ipilimumab plus nivolumab in stage III urothelial cancer: the phase 1B NABUCCO trial

Nat Med. 2024 Jan;30(1):304. doi: 10.1038/s41591-023-02500-7.

Authors

Jeroen van Dorp^#^{1

2}, Christodoulos Pipinikas^#³, Britt B M Suelmann^{2

4}, Niven Mehra^{2

5}, Nick van Dijk^{2

6}, Giovanni Marsico³, Maurits L van Montfoort^{2

7}, Sophie Hackinger³, Linde M Braaf⁸, Tauanne Amarante³, Charlaine van Steenis⁹, Kirsten McLay³, Antonios Daletzakis¹⁰, Daan van den Broek¹¹, Maaike W van de Kamp^{2

12}, Kees Hendricksen^{2

12}, Jeantine M de Feijter^{2

6}, Thierry N Boellaard^{2

13}, Richard P Meijer^{2

14}, Antoine G van der Heijden^{2

15}, Nitzan Rosenfeld^{3

16

17}, Bas W G van Rhijn^{2

12

18}, Greg Jones¹⁹, Michiel S van der Heijden^{20

21}

Affiliations

¹ Department of Molecular Carcinogenesis, Netherlands Cancer Institute, Amsterdam, The Netherlands.
² Dutch Uro-Oncology Study Group, Bilthoven, The Netherlands.
³ Inivata Ltd., Babraham Research Park, Cambridge, UK.
⁴ Department of Medical Oncology, University Medical Center Utrecht, Utrecht, The Netherlands.
⁵ Department of Medical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands.
⁶ Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
⁷ Department of Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
⁸ Core Facility Molecular Pathology & Biobanking, Netherlands Cancer Institute, Amsterdam, The Netherlands.
⁹ Genomics Core Facility, Netherlands Cancer Institute, Amsterdam, The Netherlands.
¹⁰ Department of Biometrics, Netherlands Cancer Institute, Amsterdam, The Netherlands.
¹¹ Department of Laboratory Medicine, Netherlands Cancer Institute, Amsterdam, The Netherlands.
¹² Department of Surgical Oncology (Urology), Netherlands Cancer Institute, Amsterdam, The Netherlands.
¹³ Department of Radiology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
¹⁴ Department of Urological Oncology, University Medical Center Utrecht, Utrecht, The Netherlands.
¹⁵ Department of Urology, Radboud University Medical Center, Nijmegen, The Netherlands.
¹⁶ Cancer Research UK Cambridge Institute, Cambridge, UK.
¹⁷ Cancer Research UK Major Centre Cambridge, Cancer Research UK Cambridge Institute, Cambridge, UK.
¹⁸ Department of Urology, Caritas St. Josef Medical Centre, University of Regensburg, Regensburg, Germany.
¹⁹ Inivata Ltd., Babraham Research Park, Cambridge, UK. greg.jones@inivata.com.
²⁰ Dutch Uro-Oncology Study Group, Bilthoven, The Netherlands. ms.vd.heijden@nki.nl.
²¹ Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands. ms.vd.heijden@nki.nl.

^# Contributed equally.

PMID: 37460757
DOI: 10.1038/s41591-023-02500-7

No abstract available

Publication types

Published Erratum

Grants and funding

28292/CRUK_/Cancer Research UK/United Kingdom